Invesco
DSGN icon

Invesco’s Design Therapeutics DSGN Stock Holding History

Invesco’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$310K Sell
21,429
-120,491
-85% -$1.5M ﹤0.01% 3432
2026
Q1 		$1.51M Sell
141,920
-163,837
-54% -$1.66M ﹤0.01% 2677
2025
Q4 		$2.87M Buy
305,757
+291,168
+1,996% +$2.28M ﹤0.01% 2468
2025
Q3 		$110K Buy
14,589
+225
+2% +$1.13K ﹤0.01% 3672
2025
Q2 		$48.4K Buy
14,364
+3,033
+27% +$11.3K ﹤0.01% 3726
2025
Q1 		$43.7K Sell
11,331
-252
-2% -$1.2K ﹤0.01% 3708
2024
Q4 		$71.5K Buy
+11,583
New +$67K ﹤0.01% 3662
2024
Q2 		– Sell
-10,474
Closed -$42.2K – 3903
2024
Q1 		$42.2K Sell
10,474
-463
-4% -$1.24K ﹤0.01% 3815
2023
Q4 		$29K Buy
+10,937
New +$25.1K ﹤0.01% 3787
2022
Q4 		– Sell
-10,058
Closed -$168K – 4029
2022
Q3 		$168K Sell
10,058
-79
-0.8% -$1.57K ﹤0.01% 3727
2022
Q2 		$142K Buy
+10,137
New +$137K ﹤0.01% 3817
2022
Q1 		– Sell
-9,622
Closed -$206K – 4027
2021
Q4 		$206K Buy
+9,622
New +$165K ﹤0.01% 3764

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco's DSGN Position: Q2 2026 in Review

Invesco reduced its Design Therapeutics (DSGN) stake by 85% in Q2 2026, selling an estimated $1.5M and leaving 21,429 shares worth $310K. The position accounts for ﹤0.01% of the portfolio, ranked #3432.

Invesco first reported a position in DSGN in Q4 2021 and has held it in 12 quarters since. The position peaked at $2.87M in Q4 2025. 137 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • Invesco held 21,429 shares of Design Therapeutics worth $310K as of Q2 2026.
  • Invesco sold 120,491 Design Therapeutics shares in Q2 2026, an estimated $1.5M.
  • Design Therapeutics made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #3432 holding.
  • Invesco first reported a position in Design Therapeutics in Q4 2021 and has held it in 12 quarters since.
  • Invesco's Design Therapeutics position peaked at $2.87M in Q4 2025.
  • 137 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.